These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

815 related items for PubMed ID: 27866858

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease.
    Terrelonge M, Marder KS, Weintraub D, Alcalay RN.
    J Mol Neurosci; 2016 Jan; 58(1):88-92. PubMed ID: 26330275
    [Abstract] [Full Text] [Related]

  • 4. CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease.
    Liu C, Cholerton B, Shi M, Ginghina C, Cain KC, Auinger P, Parkinson Study Group DATATOP Investigators, Zhang J.
    Parkinsonism Relat Disord; 2015 Mar; 21(3):271-6. PubMed ID: 25596881
    [Abstract] [Full Text] [Related]

  • 5. Predicting cognitive decline with non-clinical markers in Parkinson's disease (PRECODE-2).
    Yousaf T, Pagano G, Niccolini F, Politis M.
    J Neurol; 2019 May; 266(5):1203-1210. PubMed ID: 30820739
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Olfactory impairment predicts cognitive decline in early Parkinson's disease.
    Fullard ME, Tran B, Xie SX, Toledo JB, Scordia C, Linder C, Purri R, Weintraub D, Duda JE, Chahine LM, Morley JF.
    Parkinsonism Relat Disord; 2016 Apr; 25():45-51. PubMed ID: 26923521
    [Abstract] [Full Text] [Related]

  • 8. Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer's disease-associated biomarkers alterations among de novo Parkinson's disease patients: a prospective cohort study.
    Liu T, Zuo H, Ma D, Song D, Zhao Y, Cheng O.
    J Neuroinflammation; 2023 Jul 20; 20(1):167. PubMed ID: 37475029
    [Abstract] [Full Text] [Related]

  • 9. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.
    Alves G, Brønnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, Kurz MW, Andreasson U, Tysnes OB, Larsen JP, Mulugeta E.
    J Neurol Neurosurg Psychiatry; 2010 Oct 20; 81(10):1080-6. PubMed ID: 20547614
    [Abstract] [Full Text] [Related]

  • 10. CSF biomarkers and clinical progression of Parkinson disease.
    Hall S, Surova Y, Öhrfelt A, Zetterberg H, Lindqvist D, Hansson O.
    Neurology; 2015 Jan 06; 84(1):57-63. PubMed ID: 25411441
    [Abstract] [Full Text] [Related]

  • 11. Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study.
    Delgado-Alvarado M, Dacosta-Aguayo R, Navalpotro-Gómez I, Gago B, Gorostidi A, Jiménez-Urbieta H, Quiroga-Varela A, Ruiz-Martínez J, Bergareche A, Rodríguez-Oroz MC.
    Mov Disord; 2018 Nov 06; 33(11):1809-1813. PubMed ID: 30423201
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.
    Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR, Irwin DJ, Van Deerlin V, Chen-Plotkin AS, Caspell-Garcia C, Waligórska T, Taylor P, Shah N, Pan S, Zero P, Frasier M, Marek K, Kieburtz K, Jennings D, Tanner CM, Simuni T, Singleton A, Toga AW, Chowdhury S, Trojanowski JQ, Shaw LM, Parkinson’s Progression Marker Initiative.
    Acta Neuropathol; 2016 Jun 06; 131(6):935-49. PubMed ID: 27021906
    [Abstract] [Full Text] [Related]

  • 14. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
    Skogseth RE, Bronnick K, Pereira JB, Mollenhauer B, Weintraub D, Fladby T, Aarsland D.
    J Parkinsons Dis; 2015 Jun 06; 5(4):783-92. PubMed ID: 26599300
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF Aß42 and an APOE ε4 allele.
    Shahid M, Kim J, Leaver K, Hendershott T, Zhu D, Cholerton B, Henderson VW, Tian L, Poston KL.
    Neurobiol Dis; 2019 Jul 06; 127():278-286. PubMed ID: 30826425
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease.
    Siderowf A, Xie SX, Hurtig H, Weintraub D, Duda J, Chen-Plotkin A, Shaw LM, Van Deerlin V, Trojanowski JQ, Clark C.
    Neurology; 2010 Sep 21; 75(12):1055-61. PubMed ID: 20720189
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.